| 000 | 01866 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517122605.0 | ||
| 264 | 0 | _c20180221 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1179-1926 | ||
| 024 | 7 |
_a10.1007/s40262-016-0470-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTout, Mira | |
| 245 | 0 | 0 |
_aInfluence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. _h[electronic resource] |
| 260 |
_bClinical pharmacokinetics _c06 2017 |
||
| 300 |
_a635-647 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntigens, CD20 _xmetabolism |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xblood |
| 650 | 0 | 4 |
_aB-Lymphocytes _xmetabolism |
| 650 | 0 | 4 | _aBody Surface Area |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aLymphocyte Count |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 |
_aReceptors, IgG _xgenetics |
| 650 | 0 | 4 |
_aRituximab _xblood |
| 700 | 1 | _aGagez, Anne-Laure | |
| 700 | 1 | _aLeprêtre, Stéphane | |
| 700 | 1 | _aGouilleux-Gruart, Valérie | |
| 700 | 1 | _aAzzopardi, Nicolas | |
| 700 | 1 | _aDelmer, Alain | |
| 700 | 1 | _aMercier, Mélanie | |
| 700 | 1 | _aYsebaert, Loïc | |
| 700 | 1 | _aLaribi, Kamel | |
| 700 | 1 | _aGonzalez, Hugo | |
| 700 | 1 | _aPaintaud, Gilles | |
| 700 | 1 | _aCartron, Guillaume | |
| 700 | 1 | _aTernant, David | |
| 773 | 0 |
_tClinical pharmacokinetics _gvol. 56 _gno. 6 _gp. 635-647 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40262-016-0470-8 _zAvailable from publisher's website |
| 999 |
_c26551545 _d26551545 |
||